Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Avacta Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 78.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Avacta Group. This N/A consensus rating has held steady for over two years.
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in three segments: Diagnostics, Therapeutics, and Animal Health. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.